Why targeted cancer therapies have not hit the ‘bull’s-eye’  pg. 3

“We are at an unprecedented time of opportunity in the field of drug development,” Rothenberg concludes. “The gap that has existed for many years—between what we understand about the science of cancer and the way we treat cancer—is narrowing.”

Page < 1 2 3 All

View Related Articles:
Taking the blinders off: The search for better drugs